Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Toyota Motor Corp (TM) Price & Performance

Inovio Pharmaceuticals IncTrade
Toyota Motor CorpTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.78 (market cap $76.09M), while Toyota Motor Corp trades at $189.04 (market cap $223.57B). The key difference: Toyota Motor Corp is far larger — about 2938.2× Inovio Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays a 3.32% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOTM
Market Cap
$76.09M$223.57B
Sector
HealthConsumer Cyclical
52-Week High
$2.87$248.29
52-Week Low
$0.66$166.50
Enterprise Value
$47.10M$417.39B
Dividend Yield
3.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Toyota Motor Corp

Toyota Motor (TM) trades at $190.09, up 1.39% with bullish technical signals and strong fundamentals. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $7.57 exceeding expectations by 62%. Valuation remains attractive with P/E of 8.48 and P/B of 0.95, while revenue growth continues at $48.04T for 2025. Technical indicators show bullish moving averages and support at $189.

Outlook remains positive given strong hybrid vehicle demand and raised earnings guidance, though risks include China sales weakness and recall-related costs. Analyst consensus leans cautious with 62.5% hold ratings despite no sell recommendations. The stock presents value opportunity with solid cash flow generation and market leadership position.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Toyota Motor Corp

Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.

Read more on TM